Johnson & Johnson Announces Record 2025 Financial Results, On Track to Reach $100 Billion in Revenue in 2026

Joaquin Duato, Chairman of the Board and Chief Executive Officer of Johnson & Johnson, stated,2025: A Pivotal Year for Johnson & Johnson's Leapfrog Development, Unveiling a New Era of Accelerated GrowthThe company expects its sales to reach the $100 billion mark by 2026.

In 2022, Pfizer became the first biopharmaceutical company to achieve an annual revenue of $100 billion. However, since more than half of its sales came from COVID-related products, the revenue surge lasted only one year. Four years later, Johnson & Johnson is also about to reach the $100 billion milestone, and this achievement seems more sustainable.

Johnson & Johnson's current business consists of two major segments: innovative pharmaceuticals and medical technology.

The innovative pharmaceuticals segment contributed $60.4 billion in revenue by 2025, covering six major disease areas: oncology, immunology, neuroscience, cardiovascular and cerebrovascular diseases, surgery, and eye health.

Focusing on the equipment field,2025Johnson & Johnson Medical's operational sales growth5.4%, The net impact of acquisitions and divestitures on growth is1.1%, the latter mainly due toShockwaveThe acquisition. This round of growth is mainly driven by the fields of electrophysiology and cardiovascular.Abiomed、Driven by the achievements in wound closure products in general surgery.

Not long ago,Johnson & Johnson announced plans to spin off its orthopedics business, which will operate under the name DePuy Synthes. DePuy Synthes will become the largest and most comprehensive company focused on orthopedics, with leading market shares in key categories.

By region,2025Johnson & Johnson Medical's sales revenue in the United States for the year was174.08Billion USD, year-on-year growth6.6%; International Market Sales163.84Billion USD, year-on-year growth5.5%。